GlassScriptPhysician profile
Dana Hoffman
NPI 1508142670
$13,612.59
in general payments reported to CMS, 2019-2025
33 companies · $1,690 in 2025
The $1,690 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,718 · 2022: $2,939 · 2023: $3,206 · 2024: $3,059 · 2025: $1,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,955.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,380.57 | 2021-2025 | |
| Amgen INC. | $3,014.44 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $1,380.65 | 2021-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,339.55 | 2021-2025 | |
| Janssen Biotech, INC. | $641.47 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $564.84 | 2021-2024 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $416.60 | 2021-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $380.18 | 2021-2025 | |
| Genzyme Corporation | $323.53 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $281.16 | 2021-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $270.15 | 2021-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $237.92 | 2023-2025 | Idacio, Tyenne |
| Radius Health, INC. | $209.92 | 2023-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $197.33 | 2021-2024 | Strensiq |
| Mallinckrodt Hospital Products INC. | $155.63 | 2022-2024 | Acthar |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $148.12 | 2021-2025 | Actemra, Rituxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.35 | 2022-2025 | Ofev |
| Ani Pharmaceuticals, INC. | $67.75 | 2024-2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $51.85 | 2024-2025 | Crysvita |
| Horizon Therapeutics Plc | $51.10 | 2021-2022 | |
| Octapharma USA, INC. | $42.66 | 2025 | Octagam Immune Globulin (Human) |
| Sobi, INC | $40.29 | 2022-2025 | |
| Tersera Therapeutics LLC | $38.86 | 2024 | Quzyttir |
| Ferring Pharmaceuticals INC. | $36.32 | 2023-2024 | Euflexxa |
| Actelion Pharmaceuticals US, INC. | $32.46 | 2024 | Uptravi, Opsumit |
| Pacira Therapeutics, INC. | $32.36 | 2021 | |
| Pharming Healthcare, INC. | $30.66 | 2023 | Ruconest |
| Organon LLC | $28.30 | 2025 | Hadlima |
| Zimmer Biomet Holdings, INC. | $26.62 | 2023 | Allograft |
| Aurinia Pharma U.S., INC. | $21.95 | 2024 | Lupkynis |
| Kiniksa Pharmaceuticals International, Plc | $17.62 | 2024 | Arcalyst |
| Scilex Pharmaceuticals INC. | $16.67 | 2024 | |
| Celltrion USA INC. | $13.71 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.